As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Bicara Therapeutics Inc. The largest reported stake is RA Capital Management, L.P.'s, at 11.5%. 18 filings are on record since July 17, 2025 (Schedule 13D/A, March 2, 2026).
Sell to companies like Bicara Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 2,798,430 · Shared voting: 0 · Sole dispositive: 2,804,772 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 3,171,015 · Sole dispositive: 0 · Shared dispositive: 3,171,015 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: BlackRock, Inc. · Sole voting: 3,464,981 · Shared voting: 0 · Sole dispositive: 3,536,271 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
- · Holder: Vestal Point Capital, LP · Percent: 8.3% · SCHEDULE 13G/A
- · Holder: Deep Track Capital, LP · Percent: 6.21% · SCHEDULE 13G/A
Bicara Therapeutics Inc has 18 Schedule 13D or 13G filings on record since 2025-07-17. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 11.5% | 7,279,739 | SCHEDULE 13D/A, 2026-03-02 | 2026-02-26 |
| 9.6% | 5,216,969 | SCHEDULE 13G/A, 2025-07-31 | 2025-06-30 | |
| Vestal Point Capital, LP | 8.3% | 5,425,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Deep Track Capital, LP | 6.21% | 4,062,500 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.4% | 3,536,271 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| Red Tree GP, LLC | 4.8% | 3,170,509 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
| JANUS HENDERSON GROUP Ltd. | 4.8% | 3,171,015 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 4.2% | 2,804,772 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Fmr LLC | 3.2% | 2,100,929 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
Holding shares or following this stake? See who's behind Bicara Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Bicara Therapeutics Inc and the records around it.
Bicara Therapeutics Inc elsewhere on the record
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Bicara Therapeutics Inc
Get an email when Bicara Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bicara Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bicara Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bicara Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
24 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,464,981 | 0 | 3,536,271 | 0 | SCHEDULE 13G, 2026-07-27 |
| JANUS HENDERSON GROUP Ltd. | 0 | 3,171,015 | 0 | 3,171,015 | SCHEDULE 13G/A, 2026-08-13 |
| T. Rowe Price Investment Management, Inc. | 2,798,430 | 0 | 2,804,772 | 0 | SCHEDULE 13G/A, 2026-10-07 |
The latest filing identifies Bicara Therapeutics Inc by CUSIP 055477103 and gives its principal executive office as 245 MAIN STREET, CAMBRIDGE, MA 2142 (SCHEDULE 13G/A, 2026-10-07).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | Fmr LLC | 4.7% | SCHEDULE 13G/A |
| 2025-07-17 | Fmr LLC | 5.1% | SCHEDULE 13G |
| 2025-07-31 | Raymond Debbane | 9.6% | SCHEDULE 13G/A |
| 2025-08-14 | Vestal Point Capital, LP | 9.2% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 6.1% | SCHEDULE 13G/A |
| 2026-02-12 | Deep Track Capital, LP | 5.02% | SCHEDULE 13G |
| 2026-02-17 | Vestal Point Capital, LP | 6.5% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 5.9% | SCHEDULE 13G |
| 2026-03-02 | RA Capital Management, L.P. | 11.5% | SCHEDULE 13D/A |
| 2026-04-08 | T. Rowe Price Investment Management, Inc. | 10.1% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 3.2% | SCHEDULE 13G/A |
| 2026-05-08 | Red Tree GP, LLC | 4.8% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 8.3% | SCHEDULE 13G/A |
| 2026-05-15 | Deep Track Capital, LP | 6.21% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 5.1% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 4.8% | SCHEDULE 13G/A |
| 2026-10-07 | T. Rowe Price Investment Management, Inc. | 4.2% | SCHEDULE 13G/A |
Questions about who owns Bicara Therapeutics Inc
Who owns Bicara Therapeutics Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Bicara Therapeutics Inc: RA Capital Management, L.P. (11.5%, Schedule 13D/A, filed 2026-03-02), Raymond Debbane (9.6%, Schedule 13G/A, filed 2025-07-31), Vestal Point Capital, LP (8.3%, Schedule 13G/A, filed 2026-05-15), Deep Track Capital, LP (6.21%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (5.4%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Bicara Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Bicara Therapeutics Inc on this page are RA Capital Management, L.P. (11.5%), Raymond Debbane (9.6%) and Vestal Point Capital, LP (8.3%).
When did RA Capital Management, L.P. buy into Bicara Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-03-02, reporting 11.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Bicara Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 28, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 13, 2024 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| September 11, 2024 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| September 6, 2024 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| September 3, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 22, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Bicara Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.